SARS-CoV-2 Proteins and Simple T cell Test: Essential Tools for COVID-19 Research and Development

Indoor Biotechnologies has a suite of SARS-CoV-2 proteins in various expression systems, as well as a rapid whole blood T cell test in development. Join Indoor Biotechnologies scientists to discuss details of these products and technologies on our latest webinar on Wednesday, October 27th at 11am EDT.

Indoor Biotechnologies has used its proven expertise in structural biology, protein expression and purification to manufacture a suite of recombinant SARS-CoV-2 proteins, including a full-length spike protein. These proteins have been engineered, optimized and expressed in both mammalian and bacterial expression systems.

InBio^® SARS-CoV-2 proteins are validated for purity by LC-MS/MS, and their IgG reactivity tested using COVID-19 positive patients’ sera by ELISA. These proteins are manufactured under an ISO 9001:2015 certified Quality Management System.

Indoor Biotechnologies has developed a rapid whole blood T cell test as part of an Innovate UK grant for assessment of vaccine or viral induced T cell response to SARS-CoV-2. Individuals exposed to SARS-CoV-2 may not produce long-lasting protective antibodies. T cell assays may be an important complement to COVID-19 diagnostic testing and vaccine development.

Initial trials from InBio^® show that the T cell test correlates with PCR and antibody responses and that the test can be used to monitor changes in T cell responses after vaccination.

Previously, virus specific T cell tests have been difficult to standardize and require specific knowledge/equipment, which presents a significant barrier for large scale, effective testing. The InBio® simple T cell test aims to break these barriers and is being  optimized for easy implementation, enabling high throughput testing of COVID-19 T cell immunity.

The webinar will cover these products in detail, providing technical background, data, and applications.

Learning Objectives:

• Learn more on the available suite of SARS-CoV-2 proteins, including ELISA data comparing SARS-CoV-2 nucleocapsid RNA binding domain vs full-length spike proteins in determining vaccine efficiency.
• Learn more about the InBio® simple T cell test, including the development, milestones, and future goals.
• Understand how Indoor Biotechnologies’ SARS-CoV-2 resources can aid in COVID-19 research, diagnostics, and vaccine efforts.